派斯双林生物制药股份有限公司投资者关系活动记录表 编号：【2025】004 | | ☑特定对象调研 分析师会议 | □ | | --- | --- | --- | | | □媒体采访 业绩说明会 | □ | | 投资者关系活 | □新闻发布会 路演活动 | □ | | 动类别 | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称 | 易方达基金、泰康资产、工银瑞信、中欧基金、中信建投基金、广发 | | | 及人员姓名 | 基金、新华资产、幸福人寿、申万菱信、国联民生、长江证券、赢仕 | | | | 投资、汉央投资基金等 | | | 时间 | 2025 年 12 月 25 日-2026 年 1 月 4 | 日 | | 地点 | 广东、上海 | | | 上市公司接待 | 董事会秘书 赵玉林 | | | 人员姓名 | 主要问答记录如下： | | | | 1、血液制品行业发展预期？ 血液制品作为国家重要战略性储备物资及重大疾病急救药品， | | | | 具有极高的行业准入壁垒和稀缺性，虽然短期行业受药品集采及医 | | | 投资者关系活 | | | | 动主要内容介 | 保控费 ...

证券代码：000403 证券简称：派林生物 派斯双林生物制药股份有限公司投资者关系活动记录表 4、公司未来利润分配政策预期？ 公司 2024 年度现金分红金额约 2.56 亿元，现金分红金额占 2023 年度归属于上市公司股东的净利润的比率为 41.79%；公司 2025 年度 现金分红金额约 2.56 亿元，现金分红金额占 2024 年度归属于上市公 司股东的净利润的比率为 34.33%。 关于未来分红比例事项，作为国有控股上市公司，公司将继续保 持高分红比例持续回报股东。公司 2025 年 10 月 27 日召开的第十届 董事会第十八次会议审议通过了《关于子公司利润分配方案的议 案》，通过子公司持续向上市公司进行利润分配，以保证公司未来持 编号：【2025】003 | | ☑特定对象调研 分析师会议 □ | | --- | --- | | 投资者关系活 | □媒体采访 □ 业绩说明会 | | | □新闻发布会 路演活动 □ | | 动类别 | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 国泰基金、浦银安盛、鹏华基金、永赢基金、海富通基金、申万菱信、 | | 及人员 ...

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [6]. Core Insights - Roche's innovative therapy TNKase has received FDA approval for the treatment of acute ischemic stroke (AIS), marking it as the first stroke medication approved in nearly 30 years [2][6]. - The pharmaceutical sector showed a performance increase of +0.54% on March 4, 2025, outperforming the CSI 300 index by 0.62 percentage points, ranking 19th among 31 sub-industries [1][6]. - Among sub-industries, in vitro diagnostics (+2.26%), medical devices (+1.17%), and hospitals (+0.85%) performed well, while other bioproducts (-0.06%), medical research outsourcing (+0.07%), and offline pharmacies (+0.17%) lagged [1]. Summary by Sections Market Performance - The pharmaceutical sector's performance on March 4, 2025, was +0.54%, outperforming the CSI 300 index by 0.62 percentage points, with in vitro diagnostics leading at +2.26% [1]. - Notable individual stock performances included BGI Genomics (+20.00%), Shengxiang Biology (+15.24%), and Aidi Pharmaceutical (+11.31%), while Jiangsu Wuzhong (-8.80%), Zhixiang Jintai (-6.22%), and Sihuan Bio (-6.01%) faced declines [1]. Company News - Yinos announced that its clinical immunohistochemistry laboratory received CAP certification, enhancing its clinical testing business prospects [2]. - Tiantan Biological reported that its human coagulation factor IX has completed clinical ethical review and is set to begin Phase III clinical trials, with cumulative R&D investment reaching 25.5766 million yuan [2]. - Sunshine Novo has repurchased 2.716789 million shares, accounting for 2.43% of its total share capital, with a total expenditure of approximately 99.75 million yuan [3]. - Tigermed has repurchased 9.8063 million shares, representing 1.1337% of its total share capital, with a total expenditure of approximately 500.12 million yuan [3].